Canada markets closed

VBI Vaccines Inc. (LO9A.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.5400+0.0030 (+0.56%)
At close: 08:20AM CEST
Full screen
Previous Close0.5370
Open0.5400
Bid0.5720 x N/A
Ask0.5870 x N/A
Day's Range0.5400 - 0.5400
52 Week Range0.4200 - 3.0900
Volume300
Avg. Volume86
Market Cap15.285M
Beta (5Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)-9.1900
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    VBI Vaccines Reports Full Year 2023 Financial Results

    CAMBRIDGE, Mass., April 16, 2024--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.

  • Business Wire

    VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    CAMBRIDGE, Mass., April 11, 2024--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 2,272,728 of its common shares and warrants to purchase up to 2,272,728 common shares, at an offering price of $0.88 per common share and associated warrant. The warrants have an exercise

  • Business Wire

    VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    CAMBRIDGE, Mass., April 09, 2024--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has entered into definitive agreements for the sale and issuance of 2,272,728 common shares (or pre-funded warrants in lieu thereof) of VBI at an offering price of $0.88 per common share (or per pre-funded warrant in lieu thereof), in a registered direct offering priced at-the-market unde